{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:34:52Z","timestamp":1791909292034,"version":"4.3.4"},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.beha.2021.101335","type":"journal-article","created":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T21:09:07Z","timestamp":1636405747000},"page":"101335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Can venetoclax-based therapy replace 7+3 induction in fit older adults with AML?"],"prefix":"10.1016","volume":"34","author":[{"given":"James M.","family":"Foran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2021.101335_bib1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2021.101335_bib3","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.bbmt.2011.10.031","article-title":"Outcomes of allogeneic hematopoietic cell transplantation for adolescent and young adults compared with children and older adults with acute myeloid leukemia","volume":"18","author":"Majhail","year":"2012","journal-title":"Biol Blood Marrow Transplant : J. Am. Soc. Blood Marrow Transplantation"},{"key":"10.1016\/j.beha.2021.101335_bib4","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/bjh.16359","article-title":"Twenty five years of UK trials in acute myeloid leukaemia: what have we learned?","volume":"188","author":"Burnett","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2021.101335_bib5","first-page":"231","article-title":"De novo acute myeloid leukaemia in patients over 55-years-old: a population-based study of incidence, treatment and outcome. Northern Region Haematology Group","volume":"9","author":"Taylor","year":"1995","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2021.101335_bib6","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1054\/bjoc.1999.1123","article-title":"Treatment, long-term outcome and prognostic variables in 214 unselected AML patients in Sweden","volume":"82","author":"Astr\u00f6m","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.beha.2021.101335_bib7","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/bloodadvances.2019000937","article-title":"Venetoclax for AML: changing the treatment paradigm","volume":"3","author":"Pollyea","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.beha.2021.101335_bib8","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1158\/1078-0432.CCR-19-0365","article-title":"FDA approval summary: glasdegib for newly diagnosed acute myeloid leukemia","volume":"25","author":"Norsworthy","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2021.101335_bib9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-020-0281-x","article-title":"Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?","volume":"10","author":"Ferrara","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.beha.2021.101335_bib10","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1200\/JCO.2018.78.7366","article-title":"Improved survival by adding lomustine to conventional chemotherapy for elderly patients with AML without unfavorable cytogenetics: results of the LAM-SA 2007 FILO trial","volume":"36","author":"Pigneux","year":"2018","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.beha.2021.101335_bib11","doi-asserted-by":"crossref","DOI":"10.1177\/2040620720913010","article-title":"Low-intensity regimens versus standard-intensity induction strategies in acute myeloid leukemia","volume":"11","author":"Vey","year":"2020","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.beha.2021.101335_bib12","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1182\/blood.V126.23.217.217","volume":"126","author":"Foran","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2021.101335_bib13","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1182\/blood-2018-99-113950","volume":"132","author":"Foran","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.beha.2021.101335_bib14","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2021.101335_bib15","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/leu.2012.303","article-title":"Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making","volume":"27","author":"Ferrara","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2021.101335_bib16","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2021.101335_bib17","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jgo.2020.10.004","article-title":"Validation of the \"fitness criteria\" for the treatment of older patients with acute myeloid leukemia: a multicenter study on a series of 699 patients by the Network Rete Ematologica Lombarda (REL)","volume":"12","author":"Borlenghi","year":"2021","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.beha.2021.101335_bib18","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2021.101335_bib19","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.1002\/cam4.3311","article-title":"Regimen-intensity per count-recovery and hospitalization index: a new tool to assign regimen intensity for AML","volume":"9","author":"Sorror","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.beha.2021.101335_bib20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-134820","article-title":"Use of venetoclax (VEN) and hypomethylating agents (HMA) in newly diagnosed acute myeloid leukemia (AML) in the United States (US) - real world (RW) response, treatment duration, dose and schedule modifications","volume":"136","author":"Donnellan","year":"2020","journal-title":"Blood"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692621001006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692621001006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:06:10Z","timestamp":1761498370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692621001006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S1521692621001006"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2021.101335","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can venetoclax-based therapy replace 7+3 induction in fit older adults with AML?","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2021.101335","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101335"}}